Synapse - Xiuyan Wang

Results (120)

Safety and efficacy trial of escalation of plerixafor for mobilization of CD34+ hematopoietic progenitor cells (HPCs) for globin gene transfer in patients with sickle cell disease

Meeting Abstract

Boulad, F.; Shore, T. B.; Van Besien, K.; Guarneri, D.; Greenberg, J.; Minniti, C.; Wiener Fedus, S.; Perna, F.; Wang, X.; Riviere, I.; more...
Blood (2017)

Fulltext@MSK | Save

Genetic engineering and manufacturing of hematopoietic stem cells

Journal Article

Wang, X.; Rivière, I.
Molecular Therapy - Methods & Clinical Development (2017)

Fulltext@MSK | Save

Durable long-term survival of adult patients with B-ALL after CD19 CAR (19-28z) T cell therapy

Meeting Abstract

Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Purdon, T.; Brentjens, R.; Sadelain, M.
Haematologica (2017)

Fulltext@MSK | Save

Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL

Meeting Abstract

Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Santomasso, B.; Sadelain, M.; Brentjens, R.
Haematologica (2017)

Fulltext@MSK | Save

A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Meeting Abstract

Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Disease burden and transplant on long-term survival after CD19 CAR T cells in adults with relapsed acute lymphoblastic leukemia

Meeting Abstract

Park, J.; Rivere, I.; Wang, X. Y.; Senechal, B.; Curran, K.; Sauter, C.; Wang, Y. Z.; Li, D.; Brentjens, R.; Sadelain, M.
Molecular Therapy (2017)

Fulltext@MSK | Save

Selection and purification of CD34+ cells from cryopreserved cord blood units using CliniMACS Plus and CliniMACS Prodigy

Meeting Abstract

Wang, X. Y.; Stefanski, J.; Hack, A.; He, Q.; Boyle, R.; Barker, J.; Scandura, J.; Rafii, S.; Sadelain, M.; Riviere, I.
Molecular Therapy (2017)

Fulltext@MSK | Save

Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL

Meeting Abstract

Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy

Meeting Abstract

Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL

Meeting Abstract

Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
Blood (2016)

Fulltext@MSK | Save